Japanese dentists are now paying far more for palladium, a rare earth metal that is an essential ingredient for making dental crowns, due to economic sanctions imposed against Russia due to its Ukraine invasion.
Russia accounts for about 40 percent of the global palladium production.
The price of the alloy containing palladium has skyrocketed over fears of supply chain disruptions as a result of the sanctions.
In mid-December, the purchase price of palladium per 30 grams was 77,770 yen ($653), including tax. As of March 9, the price of palladium per 30 grams had surged to 125,400 yen.
According to Toshiaki Tanaka, a director of the prefectural association of doctors and dentists in Kanagawa, the dentists are not being reimbursed for their additional costs under the national medical insurance system.
Dentists prefer an alloy of gold, silver, and palladium in fashioning a dental crown due to the alloy’s strength and durability when patients want treatment covered by national health insurance.
Dental crowns that do not contain palladium are not as strong and tend to discolor over time.
Medical institutions do not get reimbursed in medical fees due to a rise in materials when they give treatment covered by the national health program because the fees are fixed.
The current material fee for the alloy using palladium is 88,530 yen per 30 grams even after the purchase price increased by 30,000 yen.
Tanaka expressed concern that the increased cost may prompt some people to put off going to a dentist, even though they are in desperate need of treatment, and called on the government to take emergency steps to resolve the problem. He suggested that a provision like a government subsidy to rein in gasoline prices be made available for palladium.


Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies
S&P Affirms Brazil’s BB Credit Rating with Stable Outlook Amid Fiscal Challenges
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



